-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on NovoCure, Lowers Price Target to $39

Benzinga·01/13/2026 12:44:01
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and lowers the price target from $42 to $39.